Novo Nordisk AS Class B NOV
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Novo Nordisk Receives EU Approval for Hemophilia Drug
Pfizer Signs $1.5 Billion Deal With Blackstone to Fund Weight-Loss-Drug Development
The FDA now says Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss
Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying.
Beleaguered Novo offers relief to investors, thanks to Wegovy pill
Novo Nordisk Lifts Outlook as Rollout of Wegovy Weight-Loss Pill Continues — Update
Novo Nordisk Lifts Guidance as Rollout of Wegovy Weight-Loss Pill Continues
Stock Spotlight
Trading Information
- Previous Close Price
- €36.74
- Day Range
- €36.65–37.04
- 52-Week Range
- €30.42–—
- Bid/Ask
- €0.00 / €0.00
- Shares Outstanding
- 4.41B
- Market Cap
- €163.29B
- Volume/Avg
- — / 156,349
Key Statistics
- Price/Earnings (Normalized)
- 10.67
- Price/Sales
- 3.68
- Dividend Yield (Trailing)
- 4.23%
- Dividend Yield (Forward)
- 4.23%
- Dividend Payment Schedule
- Mar, Aug
- Total Yield
- 5.04%
Company Profile
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Core
- Total Number of Employees
- 68,794
- Website
- https://www.novonordisk.com
Competitors
Valuation
Metric | NOV | SNY | RHHBY |
|---|---|---|---|
Price/Earnings (Normalized) | 10.67 | 12.53 | 20.84 |
Price/Book Value | 5.61 | 1.40 | 9.50 |
Price/Sales | 3.68 | 1.97 | 4.90 |
Price/Cash Flow | 9.69 | 8.40 | 15.33 |
Price/Earnings
NOV
SNY
RHHBY
Financial Strength
Metric | NOV | SNY | RHHBY |
|---|---|---|---|
Quick Ratio | 0.63 | 0.21 | 0.80 |
Current Ratio | 0.84 | 1.12 | 1.23 |
Interest Coverage | — | 9.10 | 13.49 |
Quick Ratio
NOV
SNY
RHHBY
Profitability
Metric | NOV | SNY | RHHBY |
|---|---|---|---|
Return on Assets (Normalized) | 20.15% | 8.44% | 15.81% |
Return on Equity (Normalized) | 56.25% | 15.62% | 48.77% |
Return on Invested Capital (Normalized) | 33.34% | 12.02% | 23.90% |
Return on Assets
NOV
SNY
RHHBY
Drug Manufacturers - General Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Eli Lilly and Co LLY | LOCK|#$!&$Bd | LOCK|sw | $1T | |||
| Johnson & Johnson JNJ | LOCK|yt<W&%& | LOCK|y!! | $688B | |||
| AbbVie Inc ABBV | LOCK|$kV!l@ | LOCK|$&^ | $521B | |||
| Roche Holding AG ADR RHHBY | LOCK|J@?&!y@ | LOCK|vZ@ | $387B | |||
| Merck & Co Inc MRK | LOCK|^wkfzW< | LOCK|FJt | $364B | |||
| Novartis AG ADR NVS | LOCK|LSfGQpmw | LOCK|^gy | $303B | |||
| AstraZeneca PLC AZN | LOCK|LZgN&?KQ | LOCK|rF | $287B | |||
| Amgen Inc AMGN | LOCK|X@$Q!$p | LOCK|y&J | $252B | |||
| Gilead Sciences Inc GILD | LOCK|$Nglp^! | LOCK|kj | $208B | |||
| Novo Nordisk AS ADR NVO | LOCK|?gK%!P | LOCK|@zF | $181B |
United States